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Methamphetamine (MA) dependence is associated with cognitive deficits.
Methylphenidate (MPH) has been shown to improve inhibitory control in healthy
and cocaine-dependent subjects. This study aimed to understand the neurophysiological
effects before and after acute MPH administration in active MA-dependent and control
subjects. Fifteen MA-dependent and 18 control subjects aged 18–46 years were scanned
using functional magnetic resonance imaging before and after either a single oral
dose of MPH (18 mg) or placebo while performing a color-word Stroop task. Baseline
accuracy was lower (p=0.026) and response time (RT) was longer (p<0.0001) for the
incongruent compared to congruent condition, demonstrating the task probed cognitive
control. Increased activation of the dorsolateral prefrontal cortex (DLPFC) and parietal
cortex during the incongruent and Stroop effect conditions, respectively was observed
in MA-dependent compared to control subjects (p< 0.05), suggesting the need to
recruit neural resources within these regions for conflict resolution. Post- compared
to pre-MPH treatment, increased RT and DLPFC activation for the Stroop effect were
observed in MA-dependent subjects (p<0.05). In comparison to MPH-treated controls
and placebo-treated MA-dependent subjects, MPH-treated MA-dependent subjects
showed decreased activation of parietal and occipital regions during the incongruent and
Stroop effect conditions (p<0.05).These findings suggest that in MA-dependent subjects,
MPH facilitated increased recruitment of the DLPFC for Stroop conflict resolution, and
a decreased need for recruitment of neural resources in parietal and occipital regions
compared to the other groups, while maintaining a comparable level of task performance
to that achieved pre-drug administration. Due to the small sample size, the results from
this study are preliminary; however, they inform us about the effects of MPH on the neural
correlates of cognitive control in active MA-dependent subjects.
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INTRODUCTION
Methamphetamine (MA) dependence is a global public health
problem, with a consumer market of between 15 and 16 million
people in 2007 (1). Neuroimaging studies have shown chronic
MA use in humans to be associated with cognitive deficits (2–
8), decreased gray matter density or volume (9–12), increased
white matter hyperintensities (13), and decreased white matter
integrity (14), which are thought to reflect the toxic effects of MA
on monoaminergic neurons (15–21).
Cognitive control is a broad psychological construct that refers
to the ability to: select contextually relevant information (e.g.,
attentional selection of task-relevant stimulus information), set
goals, maintain goal-directed behaviors, monitor performance,
and optimally adjust behavior based on the contextually relevant
information (22). As such, cognitive control is often viewed as a
top-down component of cognition (22). Impairment of cognitive
control, or top-down processing, is thought to be essential in the
transition from casual and voluntary drug use to drug dependence
in humans (5,23–25). Functions of cognitive control,while separa-
ble, are integrally related and include: task switching, reward-based
learning, performance monitoring, and conflict resolution (22).
The latter includes response inhibition, and more specifically the
ability to inhibit a prepotent automated response in favor of a less
familiar task-relevant response (22, 26). A common measure of
this type of response inhibition is the color-word Stroop task (26),
which is the focus of the current study.
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The color-word Stroop task consists of two conditions of inter-
est: the congruent condition, where the word color matches the
word meaning (e.g., the word “RED” displayed in red font color)
and incongruent condition, where the word color is incompatible
with the word meaning (e.g., the word “BLUE” displayed in red
font color). In both instances, the correct response is “red.” There-
fore, the incongruent condition requires the subject to respond to
a task-relevant but less familiar dimension of a stimulus (e.g., the
font color of a color-word) while inhibiting the conflicting task-
irrelevant but prepotent dimension of that stimulus (e.g., reading
the word) (26, 27). The difference in mean response time (RT)
between the incongruent and congruent conditions results in the
Stroop effect RT, also known as the Stroop interference score. A
smaller interference score reflects better response inhibition and
consequently better cognitive control (26, 27).
Behavioral studies of active MA-dependent subjects have
reported impairments in memory, manipulation of information,
and response inhibition or ability to inhibit/suppress a habitual
prepotent response (e.g., word reading) in favor of an unusual but
task-relevant response (e.g., color-naming) during performance
of the color-word Stroop task (28, 29). Additionally, similar find-
ings have been found in MA-dependent subjects after short-term
abstinence (30, 31). These studies show that the color-word Stroop
task is sensitive in detecting impairments in response inhibition
in MA-dependent subjects. While neuropsychological tests can
be used to study behavioral performance during cognitive con-
trol, they do not provide insight about the underlying neural
mechanisms. Pinpointing neural correlates of cognitive control
processes is important for studying mechanisms behind behavioral
deficits induced by MA use and may be used to define appropriate
interventions for treating MA dependence.
The Stroop task has been combined with neuroimaging to
study regional brain activations related to cognitive control and
the Stroop effect. Functional magnetic resonance imaging (fMRI)
studies of cognitive control in healthy subjects have implicated the
prefrontal cortex (PFC) (22, 32, 33), particularly the dorsolateral
prefrontal cortex (DLPFC) (34–39), the anterior cingulate cortex
(ACC) (34, 36, 37, 40–45), the parietal cortex (46), and other brain
regions including inferior frontal regions and the insula (47).
Neuroimaging studies of cognitive control in MA dependence
are few and have only been conducted in abstinent subjects.
Abstinent MA-dependent subjects displayed behavioral deficits in
cognitive control and corresponding deficits in fMRI activation of
frontal and cingulate brain regions essential for cognitive control
during performance of the Go/No-go task (3) and the color-
word Stroop task (5). However, another study found no group
differences in Stroop task performance between abstinent MA-
dependent and control subjects and although they reported signif-
icant activation of the ACC corresponding with the Stroop conflict
effect (incongruent–congruent), this was across all subjects with
no significant group differences (8).
To date, the treatment of MA dependence has consisted primar-
ily of psychosocial interventions including cognitive-behavioral
therapy and contingency management (48), which are not often
used systematically (49) and can be costly. Although several phar-
macological agents have been investigated for effectiveness in
improving outcomes related to the treatment of MA dependence,
such as decreasing MA craving or use, most agents failed to
show effectiveness (48, 50, 51). However, certain drugs have
shown promise or were associated with limited reductions in
MA or amphetamine use, including the dopaminergic agents,
modafinil (52, 53), bupropion (54, 55), dexamphetamine (56),
and methylphenidate (MPH) (51, 57).
MPH has been shown to have cognitive enhancing effects in
healthy subjects (58, 59) and in patients with attention deficit
hyperactivity disorder (ADHD), with a role in normalizing cere-
bral function in the latter (60–62). MPH improved inhibitory
control, as measured by the Stop Signal task, in cocaine-dependent
subjects in association with increased activation of the left DLPFC
(63). Moreover, MPH has been shown to normalize cingulate
activity in cocaine-dependent subjects during performance of a
rewarded drug cue-reactivity task (64), as well as patients with
ADHD during performance of cognitive control tasks (65, 66),
including the color-word Stroop task (66). Although MPH modu-
lated areas within the PFC associated with error-related processing
in cocaine-dependent subjects performing the color-word Stroop
task, it did not alter task performance (67).
MPH is an inhibitor of both the dopamine transporter and
noradrenaline transporter (68–76). Inhibition of monoamine
transporters by MPH leads to increased extracellular concentra-
tions of dopamine in the PFC (77–80) and striatum (69, 81), and
of noradrenaline in the PFC (77–80). The pharmacological effects
of MPH are similar to those of cocaine and MA (82, 83). The
overlap between the effects of MPH and those of MA suggests
MPH may be an effective agonist replacement for MA depen-
dence, and the use of MPH has been associated with positive early
findings (51, 57). For example, MPH (54 mg/day) was superior
to both aripiprazole (15 mg/day) and placebo for decreasing MA
use in MA-dependent subjects (57). Although results from the
randomized controlled trial that our sample of MA-dependent
subjects were recruited from (the parent trial) showed no dif-
ference between MPH (Concerta® ER; 54 mg/day) and placebo
in the percentage of MA-positive urine samples, a higher reten-
tion rate was found in the MPH-treated MA-dependent group in
comparison to that in the placebo-treated group (84).
The aim of this study was to investigate the behavioral and
neural correlates of cognitive control using fMRI with the color-
word Stroop task before and after an acute MPH (18 mg) challenge
compared to placebo in active MA-dependent subjects and con-
trol subjects. To the best of our knowledge, this is the first fMRI
study of cognitive control in active MA-dependent subjects, and
the first to study MPH in MA dependence using fMRI. Con-
sequently, the patterns of neural activations associated with the
color-word Stroop task in active MA-dependent subjects, both
at baseline and following MPH treatment, have not been pre-
viously reported and the effects of MPH treatment also remain
unknown. Based on previous fMRI studies of cognitive control
in abstinent MA-dependent subjects (3, 5), we hypothesized that
our sample of active MA-dependent subjects would exhibit deficits
in fMRI activation of frontal and cingulate brain regions during
conditions of cognitive conflict with or without corresponding
deficits in task performance. Since a previous study showed MPH
(20 mg) administration did not cause behavioral changes in Stroop
task performance in cocaine-dependent subjects (67), we did not
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expect the low dose of MPH (18 mg) used in the current study
to change task performance during any of the Stroop conditions
or to induce changes in neural activation during the congruent
condition, since it does not require conflict resolution. However,
we hypothesized that MPH would induce different neural activa-
tion patterns in active MA-dependent subjects relative to control
subjects during the incongruent and Stroop effect conditions.
Since MPH has been previously shown to modulate activity of
areas within the cingulate cortex (64) and PFC (67), including the
DLPFC (63) of cocaine-dependent subjects during tasks of cog-
nitive control, we hypothesized that MPH administration would
cause alterations in activation of the DLPFC and cingulate regions
of MA-dependent subjects during Stroop conflict resolution. An
exploratory whole-brain analysis method was employed to test
these hypotheses, since there have been no prior fMRI studies of
active MA-dependent subjects during tasks of cognitive control,
nor have there been studies of the effects of MPH on the brains of
MA-dependent subjects.
MATERIALS AND METHODS
SUBJECTS, DRUGS, AND TESTING PROCEDURE
Fifteen adult subjects with a history of MA dependence and
still actively using MA (four females; age 35.3± 7.0 years) were
recruited from Community Alcohol and Drug Services in Point
Chevalier, Auckland, New Zealand and 18 matched control sub-
jects with no previous history of drug dependence (six females;
age 31.1± 8.1 years) were recruited by word of mouth and adver-
tisements (Table 1). MA-dependent subjects who were eligible for
and interested in the current study were recruited from a ran-
domized controlled trial of MPH compared to placebo in active
MA-dependent subjects (the parent trial), which used percent-
age of MA-negative urine samples as its primary outcome mea-
sure (84). MA-dependent subjects were screened and diagnosed
by a consultant psychiatrist using a structured clinical interview
(SCID-I, Clinical Trials Version) (85). Data collected also included
detailed questions regarding age at first use, route of administra-
tion, average amount of MA use per day, number of days used
per week, and duration of regular use as well as self-rated level
of use (light, regular, heavy). This was used to estimate the life-
time cumulative amount of MA used (Table 1). MA-dependent
subjects also underwent physical examinations, and blood and
urine testing to ensure health. They fulfilled the following inclu-
sion criteria: (1) age between 18 and 46 years and of any ethnicity;
(2) diagnosis of MA dependence according to DSM-IV crite-
ria; current MA use was confirmed by qualitative urine drug
tests (cut-off 300µg/L); (3) urine toxicology screen testing for
MA, cocaine, opiates, cannabis, and benzodiazepine compounds,
which was negative for all except for MA and cannabis and no
current or past history of other drug dependence, such as alco-
hol, cannabis, cocaine, opioids, or benzodiazepines; (4) taking no
other prescribed medications, except for oral contraceptives and
mild analgesics when required. Exclusion criteria were: (1) past or
present Axis I psychiatric diagnosis (other than MA dependence,
but including schizophrenia and major depression); (2) neuro-
logical, thyroid, renal, gastrointestinal, or cardiovascular disease;
(3) clinically significant hepatic disease; (4) past or present ill-
nesses known to affect cognition (e.g., stroke, traumatic brain
injury, epilepsy, Parkinson’s disease, neurodegenerative disorders);
(5) risk of suicide or violent behavior; (6) glaucoma; (7) Tourette’s
disorder or tics; (8) in females, current pregnancy or lactation; (9)
any contraindications to magnetic resonance imaging (MRI) (e.g.,
claustrophobia and implanted ferromagnetic objects).
Control subjects fulfilled the same inclusion/exclusion criteria
as those with MA dependence except they were also excluded if
they had a history of drug use.
Active MA-dependent subjects were randomly divided into two
groups: eight subjects were assigned to the“MA MPH”group (four
females; age 32.8± 7.5 years) and seven subjects were assigned to
the “MA placebo” group (all males; age 38.3± 5.6 years) (Table 1).
Control subjects were also randomly divided into two groups;
8 subjects were assigned to the “control MPH” group (three
females; age 29.5± 7.5 years) and 10 subjects were assigned to
the “control placebo” group (three females; age 32.3± 8.7 years)
(Table 1).
Subjects underwent fMRI while performing the color-word
Stroop task before (pre-drug scan) and approximately 1.5 h after
Table 1 | Mean ± standard deviation (range) for demographic characteristics of subjects.
“Control MPH”
subjects (n=8)
“Control placebo”
subjects (n=10)
“MA MPH”
subjects (n=8)
“MA placebo”
subjects (n=7)
Age (years) 29.5±7.5 (23–46) 32.3±8.7 (18–44) 32.8±7.5 (22–44) 38.3±5.6 (28–46)
Gender (males/females) 5/3 7/3 4/4 7/0
Social drinking (n) 2 6 6 3
Regular nicotine use 0 0 7 6
Cannabis use – – 7 6
MA USEVARIABLES
Route of administration (smoking/IV/both) – – 7/0/1 5/2/0
Age at first use (years) – – 23.3±7.2 (12–34) 24.4±7.2 (15–32)
Duration of use (years) – – 8.8±2.7 (4–11) 13.0±7.7 (2–25)
Amount of MA used per year (g) – – 138.7±173.7 (23–520) 114.9±107.2 (11–270)
Lifetime cumulative MA use (g) – – 1320.0±1772.5 (98–5200) 1936.9±2210.6 (23–5400)
MA, methamphetamine; MPH, methylphenidate; IV, intravenous.
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(post-drug scan) receiving a single dose of their assigned medica-
tion. The capsules used for drug administration were identical in
appearance; placebo capsules contained methylcellulose and MPH
capsules contained one osmotic-controlled release oral delivery
system (OROS) MPH (Concerta® ER) tablet (18 mg). The 1.5 h
delay between doses was chosen based on the OROS MPH pro-
ducing a peak in plasma concentrations within the first 1–2 h
following administration (86, 87). All procedures were approved
by the Northern X Regional Ethics Committee of New Zealand
(Ref: NTX/08/09/089) and subjects gave written informed consent
prior to taking part in this study.
THE COLOR-WORD STROOP TASK
During the fMRI scan, the Stroop task stimuli were presented indi-
vidually at the center of a screen located 3.5 m from the subject,
and reflected into a mirror prism within the head coil. The stimuli
were presented in bold Courier New style font, size 75 against a gray
background, using E-Prime v2.0 (Psychological Software Tools,
Pittsburgh, PA, USA). The task consisted of congruent, incon-
gruent, neutral, and rest (fixation cross) blocks. The stimuli were
four color-words (“RED,” “BLUE,” “GREEN,” and “YELLOW”) in
matching font colors for the congruent condition (e.g., the word
“BLUE” displayed in blue font color) and non-matching font col-
ors for the incongruent condition (e.g., the word“BLUE”displayed
in red font color). Stimuli in the neutral condition were words
matched with the color-words for length and frequency within the
English language (“LOT,” “SHIP,” “KNIFE,” and “FLOWER”), and
presented once in each of the four colors (e.g., the word “KNIFE”
displayed in green font color). During a single fMRI run, two con-
gruent, two incongruent, and two neutral blocks were interspersed
with seven rest blocks.
Subjects performed the task twice in the scanner, once before
drug administration and once approximately 1.5 h after drug
administration. The order was counterbalanced within and across
subjects. Each task block lasted 40 s and consisted of 16 randomly
selected stimuli, each with a duration of 2000 ms and a variable
inter-stimulus interval of 400, 500, or 600 ms (average 500 ms).
During task blocks, subjects were instructed to identify the font
color of each word presented as quickly and accurately as possible,
using two magnetic-compatible two-button response boxes held
in each hand. For the red and blue target colors, subjects were
to respond using their left middle and index fingers, respectively,
and to respond to the green and yellow target colors, subjects were
to press the right index and middle fingers, respectively. Accu-
racy and RT were recorded in E-Prime v2.0. During rest blocks, a
black fixation cross was presented at the center of the screen for
16 s and subjects were instructed to take a break without closing
their eyes. The task was approximately 6 min in duration. Subjects
were trained outside the scanner on the correct finger positions
for each target color and were required to achieve a minimum
accuracy of 75% before proceeding to perform the task during
fMRI.
In this paradigm, the Stroop effect was used as an index of
response conflict in both task-related behavioral and functional
brain activation analyses. The Stroop effect was computed as the
difference in RT, accuracy, and fMRI brain activation between
incongruent and congruent conditions.
MAGNETIC RESONANCE IMAGE ACQUISITION/SCANNING
PARAMETERS
Magnetic resonance imaging was conducted at the Centre for
Advanced MRI, University of Auckland using a 1.5-T Siemens
Magnetom Avanto scanner (Siemens Medical Solutions, Erlangen,
Germany). Functional data were acquired along the AC–PC line
with a T∗2-weighted EPI sequence of 35 contiguous axial slices
(TR= 3000 ms, TE= 50 ms, flip angle= 90°, FOV= 192 mm,
matrix size= 64× 64), yielding 3 mm3 isotropic voxels. The func-
tional data were collected during a single run consisting of
118 volumes, after discarding the first three “dummy” volumes
at the beginning of each session to allow for T1 signal equi-
librium to be reached. Structural data were acquired with a
high resolution T1-weighted anatomical magnetization-prepared
rapid acquisition gradient-echo (MP-RAGE) sequence (144 slices
1.25 mm thick, TR= 2400 ms, TE= 3.61 ms, TI= 1000 ms, flip
angle= 8°, FOV= 240 mm, matrix size= 144× 192), yielding
1.25 mm3 isotropic voxel resolution.
DATA ANALYSES
Behavioral data analysis
Pre-drug analysis: baseline group effects. Two-way repeated-
measures analysis of variance (ANOVA) were conducted using
STATA (v11.2), with condition (congruent and incongruent) and
group (MA-dependent and control) as factors. Separate models
were computed for RT and accuracy. Additionally, post hoc group
difference contrasts were computed separately for each condi-
tion. For RT analyses, only trials for which correct responses were
recorded during the scanning session were included.
Post-drug minus pre-drug analysis: group–drug effects. Two-
way ANOVA analyses were conducted using STATA (v11.2) to
investigate post-drug minus pre-drug differences with group (MA-
dependent and control) and drug (MPH and placebo) as factors.
Separate models were computed for accuracy and RT for each con-
dition (congruent and incongruent) and for the Stroop effect. For
RT analyses, only trials for which correct responses were recorded
during the scanning session were included.
Functional magnetic resonance imaging data analysis
Statistical Parametric Mapping (SPM8) software (Wellcome Trust
Centre for Neuroimaging, University College London, UK)1 was
used for image processing and statistical whole-brain voxel-wise
analyses.
Functional data were motion corrected, normalized to the
Montreal Neurological Institute (MNI) space (88), resampled to
2 mm× 2 mm× 2 mm isotropic voxels and spatially smoothed
using a Gaussian smoothing kernel with full-width at half-
maximum of 8 mm× 8 mm× 8 mm.
Quality assurance was conducted by detecting artifactual vol-
ume outliers including those due to motion and de-weighting
them using the Artifact Detection Tool (ART, Massachusetts
Institute of Technology, Boston, MA, USA). For the analysis of
each subject’s fMRI time-series, a first-level statistical model was
1http://www.fil.ion.ucl.ac.uk
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constructed using a General Linear Model, including the three
experimental conditions of interest: congruent, incongruent, and
neutral. Each experimental block was convolved with the canonical
hemodynamic response function. Rest blocks were not explicitly
defined and were used as an implicit baseline. A high-pass filter
cut-off of 128 s was used in an effort to remove slow signal drifts
which were not task-related. Four contrasts were constructed for
each subject; three t -contrasts testing the congruent, incongruent,
and Stroop effect (incongruent–congruent) conditions, and the
fourth contrast being an F-contrast across all conditions, used as
a check of activity for quality assurance.
Pre-drug analysis: baseline group effects. The first analysis was
conducted using the subject-level contrast images from the pre-
drug scans to establish the neural correlates of the color-word
Stroop task in active MA-dependent subjects in comparison to
control subjects prior to drug treatment.
For within-group analyses, one-sample t -tests were conducted
in both MA-dependent and control groups to reveal areas of acti-
vation across the three conditions of interest: congruent, incon-
gruent,and Stroop effect. For between-group analyses, two-sample
t -tests were conducted to reveal group differences in activation in
the three conditions of interest. Significant clusters of fMRI acti-
vation were defined as clusters with at least 308 contiguous voxels
attaining p< 0.005 based on analysis of functional neuroimages
(AFNI)’s 3dClustSim program (89).
Post-drugminus pre-drug analysis: group–drug effects. In order
to study the effects of MPH versus placebo in both groups, blood-
oxygen-level-dependent (BOLD) activations from the pre-drug
fMRI scans were subtracted from those in the post-drug fMRI
scans. Specifically, pre-drug contrast images of interest (congru-
ent, incongruent, and Stroop effect) were subtracted from their
corresponding post-drug contrast images. This process resulted
in one “post-drug minus pre-drug” contrast image per condition
per subject. Group-level 2× 2 (group× drug) between-subject
ANOVAs were conducted using the subject-level“post-drug minus
pre-drug” contrast images as inputs, to investigate group dif-
ferences in fMRI activation across the three Stroop task condi-
tions. T -contrasts were used to investigate group× drug interac-
tions, within-group fMRI activation patterns and between-group
differences in fMRI activation.
Significant clusters of fMRI activation were defined as clusters
with at least 290 contiguous voxels attaining p< 0.005 based on
AFNI’s 3dClustSim program (89).
Anatomical labeling was performed using a custom script
within MatLab named peak_nii2 and the automated anatomical
labeling (AAL) atlas (90).
RESULTS
DEMOGRAPHICS
There were no significant effects of group, drug, or group× drug
interactions for age (Table 1). Chi-square tests were used to test
differences in categorical variables; however, due to the small
2http://www.nitrc.org/projects/peak_nii
sample sizes, at least one cell had a count of 5 or less and the
Fisher’s Exact Test (FET) statistic was reported. There were no
group differences in gender (FET, p= 0.448) or alcohol use (FET,
p= 0.084). However, there were significant group differences in
tobacco smoking (FET,p< 0.0001) between active MA-dependent
and control groups. The same is also true across the four sub-
groups. Two-sample independent t -tests between the “MA MPH”
and “MA placebo” groups revealed no significant group differ-
ences in cannabis use status (FET, p= 0.733) or MA use vari-
ables such as age at first use (T 13=−0.317, p= 0.756), dura-
tion of use (T 13=−1.478, p= 0.163), amount of MA used per
year (T 13= 0.314, p= 0.759), and lifetime cumulative MA use
(T 13= -0.600, p= 0.559) (Table 1).
BEHAVIORAL RESULTS
Pre-drug analysis: baseline group effects
Accuracy and RT data by group and condition are presented
in Table 2. Analysis of the mean percentage of trials that sub-
jects performed correctly revealed a significant effect of condi-
tion (F1,31= 5.493, p= 0.026 – congruent> incongruent), but
no significant effect of group (F1,31= 1.436, p= 0.240) or con-
dition× group interaction (F1,31= 1.652, p= 0.208).
For mean RTs, there were significant effects of condi-
tion (F1,31= 45.363, p< 0.0001 – incongruent> congruent)
and group (F1,31= 4.916, p= 0.034 – MA-dependent> control),
but no significant group× condition interaction (F1,31= 1.485,
p= 0.232).
Post hoc tests of each condition revealed that MA-dependent
subjects were significantly slower than control subjects for
both incongruent trials (989.27± 20.03 versus 901.28± 18.28 ms;
mean± standard error, p= 0.0028) and congruent trials
(883.50± 20.03 versus 748.77± 18.28 ms; mean± standard error,
p< 0.0001) (Table 2). For the Stroop effect, MA-dependent sub-
jects had lower RTs (105.77± 36.84 ms; mean± standard error)
than control subjects (152.50± 16.95 ms; mean± standard error);
however, this was not statistically significant (Table 2).
Table 2 | Mean ± standard error for accuracy and response time during
performance of the color-word Stroop task prior to drug
administration (baseline group effects).
Measure Controls MA-dependent p-Value
ACCURACY (% CORRECT)
Congruent 96.6±1.1 93.7±1.2 0.0737
Incongruent 95.4±1.1 89.7±1.2 0.0009
Stroop effect –
(congruent–incongruent)
1.2±0.5 4.0±2.3 0.2082
REACTIONTIME (MS)
Congruent 748.77±18.28 883.50±20.03 <0.0001
Incongruent 901.28±18.28 989.27±20.03 0.0028
Stroop effect –
(incongruent–congruent)
152.50±16.95 105.77±36.84 0.2322
p-values are two-sided. Significant values are in bold italics.
MA, methamphetamine.
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Post-drug minus pre-drug analysis: group–drug effects
There were no significant main effects or interactions of group or
drug for any of the three conditions for accuracy (Table 3). Analysis
of the mean RT revealed a significant main effect of group for the
Stroop effect condition (F1,29= 5.15, p= 0.031), but no signifi-
cant effect of drug or group× drug interaction for RT during the
Stroop effect condition and no significant main effects or inter-
actions for RT during the congruent and incongruent conditions
(Table 3). An increase in RT during the Stroop effect condition was
observed in MA-dependent subjects post-drug compared to pre-
drug administration (67.34± 26.10 ms; mean± standard error)
relative to controls (3.35± 19.24 ms; mean± standard error). A
trend was observed (F1,29= 4.06,p= 0.053) for a decreased Stroop
effect RT post-drug compared to pre-drug administration in all
subjects who received MPH (3.10± 24.06 ms) relative to those
who received placebo (60.05± 21.37 ms).
FUNCTIONAL MAGNETIC RESONANCE IMAGING RESULTS
Pre-drug analysis: baseline group effects
Within-group results. For the congruent and incongruent con-
ditions, robust activations were observed in the calcarine fissure,
inferior occipital gyrus, middle occipital gyrus (MOG), fusiform
gyrus, inferior parietal lobule (IPL), superior parietal gyrus (SPG),
precentral gyrus, post central gyrus, and supplementary motor
area, of both MA-dependent and control groups (p< 0.05 cluster-
corrected). Additionally, activations in the control group were
observed in the supramarginal gyrus, inferior temporal gyrus
(ITG), superior temporal gyrus (STG), inferior frontal gyrus
(IFG), and superior occipital gyrus (SOG) in response to the con-
gruent condition only, and in the superior frontal gyrus (SFG) dur-
ing the incongruent condition only (p< 0.05 cluster-corrected).
Control subjects showed activation in the middle frontal gyrus
(MFG) during both the congruent and incongruent conditions
(p< 0.05 cluster-corrected). In contrast, activations in the MA-
dependent group were observed in the anterior cingulate gyrus
(ACG), and middle cingulate gyrus (MCG) during the congruent
condition only, the SOG, precuneus, and ITG during the incongru-
ent condition only and the supramarginal gyrus, IFG, MFG, SFG,
and middle temporal gyrus (MTG) in response to both congruent
and incongruent conditions (p< 0.05 cluster-corrected).
Control subjects exhibited no significant activations corre-
sponding to the Stroop effect. However, increased activation of
the IPL was observed in the MA-dependent group (p< 0.05
cluster-corrected).
Between-group results. There were no differences in fMRI acti-
vation between MA-dependent and control groups during the
congruent condition (Table 4). However, the two groups signif-
icantly differed during the incongruent and Stroop effect condi-
tions, with the MA-dependent subjects exhibiting greater fMRI
activation than control subjects (Table 4).
During the incongruent condition, MA-dependent subjects
showed greater activation than control subjects in the right
SFG (Figure 1A) and right MFG (Figure 1B) (p< 0.05 cluster-
corrected).
For the Stroop effect, MA-dependent subjects exhibited greater
activation than control subjects of the left (Figure 2A) and right
IPL (Figures 2B,C) (p< 0.05 cluster-corrected).
Post-drug minus pre-drug analysis: group–drug effects
Within-group results. During the congruent condition, there
were no significant changes in fMRI activation post- compared
to pre-drug administration in any of the four groups.
For the incongruent condition, the “control MPH” group
showed increased activation post- compared to pre-MPH admin-
istration of the left and right IPL, left SPG, left IFG, left MFG,
right STG, right MTG, right SOG, left and right MOG, and
left and right MCG (p< 0.05 cluster-corrected). The “control
placebo” group exhibited increased activation post- compared to
pre-placebo administration of the right MTG, right STG, and right
MOG (p< 0.05 cluster-corrected). Whereas the“MA MPH”group
showed no significant change in activation post- compared to pre-
MPH administration during the incongruent condition, the “MA
placebo” group exhibited increased activation of the left and right
MOG, left and right SOG, left and right cuneus, left SPG, and right
precuneus (p< 0.05 cluster-corrected).
Table 3 | Mean ± standard error for post-drug minus pre-drug measures of accuracy and response time during performance of the color-word
Stroop task (group–drug effects).
Measure Controls MA-dependent
MPH Placebo MPH Placebo
ACCURACY (% CORRECT)
Congruent 5.9±3.5 0.3±3.2 2.4±3.5 2.6±3.8
Incongruent 5.5±4.5 −7.8±4.0 1.0±4.5 −1.9±4.8
Stroop effect – (congruent–incongruent) 0.4±3.6 8.1±3.2 1.4±3.6 4.4±3.9
RESPONSETIME (ms)
Congruent −62.51±28.32 −56.60±25.33 −88.57±28.32 −110.75±30.28
Incongruent −100.71±41.66 −20.00±37.26 −44.16±41.66 −17.19±44.54
Stroop effect – (incongruent–congruent) −38.21±30.97 36.60±27.70 44.41±30.97 93.55±33.11
Values represent post-drug minus pre-drug measures.
MA, methamphetamine; MPH, methylphenidate.
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Table 4 |Whole-brain two-sample t -test analyses of group differences
in blood-oxygen-level-dependent activation during the three Stroop
conditions.
Condition
(t -contrast)
Cluster
size
(voxels)
Regions of
peak
voxels
HS MNI
co-ordinates
(mm)
Peak t -
statistic
x y z
Congruent Control>MA, p<0.05 cluster-corrected
Nil Nil Nil Nil Nil Nil Nil
MA> control, p<0.05 cluster-corrected
Nil Nil Nil Nil Nil Nil Nil
Incongruent Control>MA, p<0.05 cluster-corrected
Nil Nil Nil Nil Nil Nil Nil
MA> control, p<0.05 cluster-corrected
1743 Superior
frontal gyrus
R 28 4 60 5.73
21 14 58 5.69
20 6 50 5.13
Middle frontal
gyrus
R 30 10 46 3.84
Stroop effect Control>MA, p<0.05 cluster-corrected
Nil Nil Nil Nil Nil Nil Nil
MA> control, p<0.05 cluster-corrected
1680 Inferior parietal
lobule
R 48 −48 52 4.62
54 −40 56 4.27
319 Inferior parietal
lobule
L −46 −54 58 3.81
−54 −42 48 3.31
Significant clusters of activation were defined as clusters with at least 308 con-
tiguous voxels attaining p<0.005. Co-ordinates represented are in MNI space.
HS, hemisphere; L, left; R, right.
During the Stroop effect condition, control and MA-dependent
subjects showed no significant change in fMRI activation following
placebo administration. However, following MPH administration,
the “control MPH” group showed increased activation of the left
MOG, left IPL, left SPG, right MCG, left ACG, left SFG, left IFG,
and right supramarginal gyrus, and the “MA MPH” group exhib-
ited increased activation of the right IFG and right MFG (p< 0.05
cluster-corrected).
Between-group results. For the congruent condition, there were
no significant group differences in fMRI activation post- compared
to pre-drug administration (Table 5).
During the incongruent condition, there was a significant
group× drug interaction, whereby the “MA placebo” group
showed increased activation post- compared to pre-drug adminis-
tration relative to the “MA MPH” group of the left and right SOG
(Figure 3A), right MOG, and left SPG (Figures 3B,C) (p< 0.05
cluster-corrected) (Table 5). Following MPH administration, the
“control MPH” group showed increased activation compared to
the “MA MPH” group of the right IPL (Figures 4A,B) (p< 0.05
cluster-corrected) (Table 5).
FIGURE 1 |Whole-brain two-sample t -test results for the incongruent
condition showing pre-drug MA-dependent> control group differences
in activation of: (A) the right superior frontal gyrus [peak voxel MNI
co-ordinates (mm): (28, 4, 60);T 31 = 5.73, p<0.05 cluster-corrected],
and (B) the right middle frontal gyrus [peak voxel MNI co-ordinates
(mm): (30, 10, 46);T 31 =3.84, p<0.05 cluster-corrected]. The scale
represents the color (from red to yellow) of the cluster corresponding to the
increasing t -statistic. The structural image represents the IXI550 average
normal brain which has been registered to the MNI152 space with
corresponding inferior–superior co-ordinates.
During the Stroop effect condition, the “control MPH”
group showed increased activation post- compared to pre-drug
administration relative to the “MA MPH” group of the left
(Figure 5A) and right MOG (Figure 5B) (p< 0.05 cluster-
corrected) (Table 5). No other group comparisons exhibited sig-
nificant differences in fMRI activation during the Stroop effect
condition.
DISCUSSION
To the best of our knowledge, this is the first fMRI study to
investigate the effects of MPH on cognitive control in active
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FIGURE 2 |Whole-brain two-sample t -test results for the Stroop effect
condition showing pre-drug MA-dependent> control group differences
in activation of: (A) the left inferior parietal lobule [peak voxel MNI
co-ordinates (mm): (−46, −54, 58);T 31 =3.81, p<0.05
cluster-corrected], (B) the right inferior parietal lobule [peak voxel MNI
co-ordinates (mm): (48, −48, 52);T 31 =4.62, p<0.05 cluster-corrected],
and (C) Plot of the mean± standard error parameter estimates
representing the percentage blood-oxygen-level-dependent signal
change within the right inferior parietal lobule. The scale represents the
color (from red to yellow) of the cluster corresponding to the increasing
t -statistic. The structural image represents the IXI550 average normal brain
which has been registered to the MNI152 space with corresponding
inferior–superior co-ordinates.
Table 5 |Whole-brain 2×2 between-subject ANOVA analyses of group
differences in blood-oxygen-level-dependent activation during the
three Stroop conditions.
Condition Cluster
size
(voxels)
Regions of
peak
voxels
HS MNI
co-ordinates
(mm)
Peak t -
statistic
x y z
Congruent Nil Nil Nil Nil Nil Nil Nil
Incongruent “MA placebo”>“MA MPH,” p<0.05 cluster-corrected
936 Superior
occipital gyrus
L −20 −88 44 4.54
R 17 −92 34 3.53
Superior
parietal gyrus
L −8 −82 52 4.49
Middle
occipital gyrus
R 40 −81 27 3.65
“Control MPH”>“MA MPH,” p<0.05 cluster-corrected
293 Inferior parietal
lobule
R 56 −36 54 3.34
Stroop effect “Control MPH”>“MA MPH,” p<0.05 cluster-corrected
332 Middle
occipital gyrus
L −32 −82 30 4.18
360 Middle
occipital gyrus
R 45 −80 24 3.79
Significant clusters of activation were defined as clusters with at least 290 con-
tiguous voxels attaining p<0.005. Co-ordinates represented are in MNI space.
HS, hemisphere; L, left; R, right.
MA-dependent subjects in comparison to control subjects. Due to
the small sample sizes used, the results of this study are preliminary
and future studies with larger sample sizes are warranted to
validate these results.
PRE-DRUG ANALYSIS: BASELINE GROUP EFFECTS
Behavioral results
Consistent with previous literature, there were differences in RT
but not accuracy during performance of the Stroop task between
MA-dependent and control subjects prior to drug administration
(5, 8, 31). Analyses of both accuracy and RT showed a signifi-
cant main effect of condition, whereby both groups showed the
typical Stroop interference effect with lower accuracy and longer
RTs during the incongruent condition relative to the congruent
condition. With respect to RT, there was also a significant main
effect of group, whereby MA-dependent subjects exhibited slower
responses than control subjects across both congruent and incon-
gruent conditions. Longer RTs may reflect slower motor responses
in MA-dependent subjects in comparison to healthy control sub-
jects, as has been previously reported in substance-use disorders
(91), and more specifically in stimulant dependence (92).
There were no statistically significant group differences in RT
corresponding to the Stroop effect (incongruent RT minus con-
gruent RT). However, the MA-dependent group displayed a lower
mean RT corresponding to the Stroop effect in comparison to
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FIGURE 3 |Whole-brain 2×2 between-subject ANOVA results for the
incongruent condition showing post- minus pre-drug “MA
placebo”>“MA MPH” group differences in activation of: (A) the right
superior occipital gyrus [peak voxel MNI co-ordinates (mm): (17, −92,
34);T 29 = 3.53, p<0.05 cluster-corrected], (B) the left superior parietal
gyrus [peak voxel MNI co-ordinates (mm): (−8, −82, 52);T 29 =4.49,
p<0.05 cluster-corrected], and (C) Plot of the mean± standard error
parameter estimates representing the percentage blood-oxygen-
level-dependent signal change post- compared to pre-drug
administration within the left superior parietal gyrus. The scale
represents the color (from red to yellow) of the cluster corresponding to the
increasing t -statistic. The structural image represents the IXI550 average
normal brain which has been registered to the MNI152 space with
corresponding inferior–superior co-ordinates.
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FIGURE 4 | (A)Whole-brain 2×2 between-subject ANOVA results for
the incongruent condition showing post- minus pre-drug “Control
MPH”>“MA MPH” group differences in activation of the right inferior
parietal lobule [peak voxel MNI co-ordinates (mm): (56, −36, 54);
T 29 =3.34, p<0.05 cluster-corrected], and (B) Plot of the
mean± standard error parameter estimates representing the
percentage blood-oxygen-level-dependent signal change post-
compared to pre-drug administration within the right inferior parietal
lobule. The scale represents the color (from red to yellow) of the cluster
corresponding to the increasing t -statistic. The structural image represents
the IXI550 average normal brain which has been registered to the MNI152
space with corresponding inferior–superior co-ordinates.
control subjects. This non-significant effect may have resulted
from a smaller difference amongst MA-dependent subjects
between congruent and incongruent RTs.
Although there have been studies which reported no differ-
ences in Stroop performance between abstinent MA-dependent
individuals and control subjects (8, 93), our RT results do not
replicate findings from several other studies that reported behav-
ioral differences during the Stroop task in abstinent (5, 31) and
active MA-dependent individuals (28, 29). For example, in cog-
nitive studies of active MA-dependent individuals using neu-
ropsychological tests, Simon and colleagues observed no group
differences in performance during Stroop words, Stroop colors, or
Stroop interference scores (28, 29). However, they showed worse
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FIGURE 5 |Whole-brain 2×2 between-subject ANOVA results for the
Stroop effect condition showing post- minus pre-drug “control
MPH”>“MA MPH” group differences in activation of: (A) the left
middle occipital gyrus [peak voxel MNI co-ordinates (mm): (−32, −82,
30);T 29 =4.18, p<0.05 cluster-corrected], and (B) the right middle
occipital gyrus [peak voxel MNI co-ordinates (mm): (45, −80, 24);
T 29 =3.79, p<0.05 cluster-corrected]. The scale represents the color
(from red to yellow) of the cluster corresponding to the increasing
t -statistic. The structural image represents the IXI550 average normal brain
which has been registered to the MNI152 space with corresponding
inferior–superior co-ordinates.
performance on the Stroop color-words (equivalent to the incon-
gruent condition of our version of the Stroop task) amongst active
MA-dependent users (28, 29). The combination of normal per-
formance on Stroop words and colors and worse performance
on the Stroop color-words has been previously thought to be
indicative of generalized brain atrophy (29, 94). The discrep-
ancy in our findings from those of Simon and colleagues’ (28,
29) may be attributed to the different versions of the Stroop task
used, which may not be directly comparable. The lack of signifi-
cant difference in mean RT for the Stroop effect, combined with
the absence of a condition× group interaction in RT or accu-
racy in the current study, suggest that MA-dependent subjects
were no worse than control subjects in their behavioral Stroop
interference scores. Hence, the behavioral results from the current
study cannot be used to predict generalized brain atrophy. This is
in accordance with the results of our voxel-based morphometry
analysis of the same subject samples, which showed no differences
in cortical GM volumes between active MA-dependent and control
subjects (95).
fMRI results
In response to the Stroop effect condition, MA-dependent subjects
showed significant BOLD activations within the inferior parietal
cortex, while control subjects did not exhibit any change in fMRI
activation. Although control subjects appeared to have a larger
behavioral Stroop effect than MA-dependent subjects, this was
not statistically significant. Therefore, the absence of change in
neural activation in response to the Stroop effect for control sub-
jects may suggest the task was not difficult enough for this group
of subjects. For example, the task may require more blocks to elicit
a brain response to the Stroop effect condition in healthy con-
trol subjects. Nonetheless, behavioral and fMRI activation changes
observed in the MA-dependent group during both the incongru-
ent and Stroop effect conditions suggest the task was of sufficient
difficulty to elicit a response in MA-dependent subjects.
Increased BOLD activation of the PFC and parietal cortex was
observed in both control and MA-dependent groups during the
congruent and incongruent conditions of the color-word Stroop
task. This finding of increased activation of prefrontal and parietal
regions is opposite to our hypothesis that MA-dependent subjects
would exhibit deficits in fMRI activation of frontal regions. Since
this hypothesis was based on previous studies of MA-dependent
subjects who were abstinent, it is possible that the discrepancy
in findings may be attributed to the active user status of our
sample of MA-dependent subjects. Successful conflict resolution
during the Stroop task is expected to involve activity of frontal
and superior parietal cortices, which are implicated in top-down
stimulus biasing (46). The role of prefrontal and parietal regions
in tasks involving cognitive control, particularly response inhibi-
tion, is well-established in healthy individuals (32, 33, 37–39, 42,
45, 46, 96, 97) and those with drug dependence (5, 8). In chronic
MA-dependent subjects, abnormalities in regional cerebral glu-
cose metabolism have been observed in the PFC, ACC, and parietal
cortex (98–100).
Previous studies of cognitive control have documented the
ACC (3, 5, 8, 34, 36, 37, 40–43) and DLPFC (5, 8, 34–39), which
anatomically spans the SFG, IFG, and MFG (22, 101) as the
primary neural substrates of conflict monitoring and cognitive
control, respectively. The cingulate cortex was activated in MA-
dependent subjects only when performing the congruent condi-
tion, during which they showed increased activation of the MCG.
Activation of the cingulate cortex during the congruent and not
the incongruent condition is somewhat unusual; as the cingulate
cortex, specifically the ACC, has been generally implicated during
the performance of incongruent conditions (8, 37) or in response
to the Stroop effect (5), suggesting a role in performance moni-
toring (37). Although previous fMRI studies using the Stroop task
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in MA-dependent subjects found significant group differences in
activation of the ACC during the incongruent condition, they were
conducted in abstinent subjects (5, 8). Moreover, one of these stud-
ies did not investigate group differences in whole-brain activation
and used regions of interest with specific hypotheses surrounding
the ACC and PFC (8). Therefore, previous findings from fMRI
studies using the Stroop task in abstinent subjects may not be
directly comparable with our results. It is possible that active MA-
dependent subjects do not need to activate the ACC during the
Stroop conflict conditions.
The DLPFC has been shown to be active during color-naming
conditions, confirming a role in the implementation of control
(37). Using fMRI, the DLPFC has also been shown to be active in
response to successful inhibition of unpredictable No-go events
during a “sustained attention to response” task (102) and during
the Stroop task (33). Activation of the DLPFC was observed in the
current study, specifically in the SFG and MFG of MA-dependent
subjects and the MFG of control subjects in response to both con-
gruent and incongruent conditions. A significant between-group
difference was found whereby MA-dependent subjects showed
increased activation of the right SFG and MFG in comparison
to control subjects during the incongruent condition. Increased
SFG activation has been previously reported following successful
conflict adaptation, corresponding with increased cognitive con-
trol in healthy individuals (35). The MFG is an important part of
the cerebral circuit that underlies top-down control processes such
as cognitive control, and has been specifically implicated in cog-
nitive control during conflict adaptation (35, 103). In a previous
study, abstinent cocaine-dependent subjects exhibited increased
activation within the DLPFC, specifically the MFG, during con-
flict conditions of the color-word Stroop task in comparison to
healthy control subjects (67). It is possible that MA-dependent
subjects needed to recruit additional neural resources within the
DLPFC in order to perform the task correctly and to the same level
of efficiency as control subjects.
Increased activation of the IFG was also observed in the MA-
dependent group during both congruent and incongruent con-
ditions and in the control group during the congruent condition
only. The IFG has been implicated in inhibitory control (104)
and in the exertion of self-control through modulation by the
DLPFC (105). Patients with lesions in the right IFG have impaired
inhibitory control (106), and neuroimaging studies have shown
that the IFG is involved in tasks requiring response inhibition
such as the Go/No-go task (107, 108).
Both MA-dependent and control subjects activated the IPL and
SPG within the parietal cortex during the incongruent condition.
However, only MA-dependent subjects activated the IPL during
the Stroop effect condition, resulting in a significant between-
group difference in fMRI activation in this region. Both the
incongruent and Stroop effect conditions present subjects with a
stimulus-based conflict, requiring the subject to respond to word
color, an unusual task-relevant stimulus feature and inhibit the
word reading response, a prepotent response (26, 27). Stroop con-
flict resolution is thought to occur via a stimulus-biasing strategy
(103, 109, 110), which involves modulation of activity in the pari-
etal cortex (46). The parietal cortex is thought to be the origin of
top-down signals (received from the PFC) that initiate selective
attentional bias in favor of the task-relevant feature by amplifying
visual processing toward it (111–114). The superior parietal cortex
is involved in Stroop conflict resolution in healthy humans (46),
which corresponds well with both control and MA-dependent
subjects activating the SPG during the incongruent condition. In
healthy subjects, response inhibition during Stroop conflict con-
ditions has also been associated with fMRI activity in the inferior
parietal cortex, which encompasses the IPL (32, 33). This process is
also thought to result from biasing toward processing of the task-
relevant stimulus feature involving similar top-down modulation
from the PFC to the inferior parietal cortex (32, 115). The IPL
is known to be involved in other tasks requiring response inhibi-
tion including the Simon task (33), Go/No-go task (97, 116, 117),
and the Stop paradigm task (117). Although parietal regions have
not been previously implicated in fMRI studies of MA-dependent
subjects during cognitive control, increased IPL activation was
reported in recently abstinent MA-dependent subjects with lower
error rates, and during the most unpredictable condition while
performing the two-choice prediction task (6). Our results suggest
that MA-dependent subjects who are active users require recruit-
ment of additional neural resources in the inferior parietal cortex
for Stroop conflict resolution with similar behavioral efficiency to
control subjects.
During the congruent and incongruent conditions of the
Stroop task, both groups demonstrated robust activations of
vision-related regions including the calcarine fissure and occip-
ital cortex. The visual pathways including the occipital cortex
are not typically associated with the cognitive control aspect of
the Stroop task. However, during the Stroop task, subjects are
instructed to respond to the ink color of a presented word (task-
relevant stimulus) and inhibit their prepotent response to read
the word (task-irrelevant stimulus) (26, 27). In order to achieve
cognitive control, visual pathways may be activated in an effort
to bias selective attention toward task-relevant stimulus features
and distinguish them from task-irrelevant distracter features of
the stimulus, leading to amplified neural processing of target
(task-relevant) stimulus features (103).
POST-DRUG MINUS PRE-DRUG ANALYSIS: GROUP–DRUG EFFECTS
Behavioral results
Behaviorally, subjects did not differ in task accuracy post-drug
compared to pre-drug administration. For the Stroop effect con-
dition, MA-dependent subjects exhibited significantly longer RTs
(higher interference scores) post-drug compared to pre-drug
administration relative to control subjects, irrespective of drug
treatment. However, this effect was more pronounced in placebo-
treated MA-dependent subjects than those treated with MPH.
Higher interference scores post- compared to pre-drug admin-
istration in MA-dependent subjects may be due to increased
distractibility toward the end of the study session in compari-
son to the start of the session. Although acutely, MA improves
attention and concentration (118), it has been clinically observed
to cause increased distractibility (31). Furthermore, most of our
MA-dependent subjects appeared distractible, despite scoring over
75% on the practice version of the Stroop task outside the scanner.
For example, some subjects showed difficulty following conversa-
tion, while others found it challenging to follow instructions. This
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observation was thought to be worse during the second half of
the study session than the first half. However, the increase in dis-
tractibility may have been tempered in the“MA MPH”group as we
observed smaller, but not significantly different increases in Stroop
effect RT post- compared to pre-drug administration relative to
the “MA placebo” group.
Although there were no significant drug effects for mean RT,
a trend was observed for a decreased Stroop effect RT in all sub-
jects who received MPH compared to those who received placebo.
This trend suggests that MPH administration caused improve-
ment in task performance, manifested by a decreased interference
score (Stroop effect RT) in all subjects, irrespective of group
membership.
Several studies in children with ADHD showed improved per-
formance following MPH administration during the color-word
Stroop task (119) and the Go/No-go task (inhibitory control)
(120) in both healthy children and those with ADHD, and dur-
ing a rewarded continuous performance task (attention but not
impulsiveness errors) in children with ADHD (121). MPH has
also been shown to improve response inhibition in healthy adult
subjects, with specific improvements in stop signal RT and RT
variability during performance of the stop signal inhibition task,
without changing overall speed (122). However, there have been
studies that reported no change in Stroop task performance fol-
lowing MPH administration in patients with ADHD (123) or
those with cocaine-dependence and their comparison subjects
(67). Nonetheless, our study showed a trend for improved task per-
formance in active MA-dependent subjects and their comparison
subjects following MPH administration relative to placebo. Based
on this trend, we cannot sustain our hypothesis that acute low-
dose MPH (18 mg) administration would not change Stroop task
performance efficiency, and studies using higher doses of MPH
may be needed to come to any definitive conclusion.
fMRI results
In accordance with our hypothesis, there were no within- or
between-group differences in fMRI activation post- compared to
pre-drug administration during the congruent condition. Since
the congruent condition does not present cognitive conflict,
response inhibition is not required and therefore an acute dose
of MPH would not be expected to induce a difference in task
performance or neural activation.
There is an established role for the DLPFC (37), including the
IFG (104, 106), MFG (8, 35, 103), and SFG (35) in conflict res-
olution and cognitive control. MPH administration resulted in
increased activation of the left IFG and MFG during the incon-
gruent condition and the left IFG and SFG during the Stroop
effect condition in “control MPH” subjects; an effect that was not
observed in the other three groups. The effects of MPH on the
DLPFC are well-known; it has been shown to cause increased
regional cerebral blood flow in the bilateral DLPFC in children
with ADHD who were previously treatment-naïve (124). The IFG
and MFG are known to be activated in response to the incongruent
condition of the color-word Stroop task in healthy subjects and
those with cocaine-dependence treated with MPH and placebo
(67). MPH is also known to increase prefrontal activation equally
in children with ADHD and healthy matched controls during the
Go/No-go task (120). Following an acute dose of MPH, healthy
control children showed increased activation of the right IFG in
comparison to children with ADHD during a task of vigilant
attention (121). However, this may not have been specific to MPH,
as control children also exhibited increased activation of right IFG
relative to those with ADHD following placebo (121). MPH has
also been shown to cause an increase in activation of the MFG in
healthy subjects performing tasks of visual attention and working
memory, which was positively correlated with increasing cognitive
load of the working memory task (125).
Although “MA MPH” subjects did not exhibit differences in
BOLD activation within the DLPFC post- compared to pre-MPH
administration during the congruent and incongruent conditions,
there was a larger difference in activation of the IFG and MFG
within the right DLPFC of these subjects between the incongru-
ent and congruent conditions. This difference in activation post-
compared to pre-MPH administration resulted in an increase
in right DLPFC activation corresponding with the Stroop effect,
which was accompanied by an increased Stroop effect RT (inter-
ference score). However, it is worth noting that the increase in
Stroop effect RT (incongruent RT–congruent RT) resulted from a
smaller improvement/reduction in RT for the incongruent con-
dition compared to the congruent condition post- relative to
pre-MPH administration (Table 3). MPH administration has
been shown to modulate neural activation within the DLPFC
of cocaine-dependent subjects during tasks of cognitive control
(63). Therefore, taken together, increased RT and right DLPFC
activation post- compared to pre-MPH administration during the
Stroop effect condition, suggest an MPH-facilitated recruitment of
additional neural resources within the DLPFC of MA-dependent
subjects for Stroop conflict resolution. This finding supports our
hypothesis that MPH administration would cause alterations in
activation of the DLPFC of MA-dependent subjects during Stroop
conflict resolution.
Between-group differences in fMRI activation were reported
mainly within the parietal–occipital cortices,with“MA MPH”sub-
jects exhibiting a greater decrease in activity within these regions
during the incongruent condition compared to “MA placebo” and
“control MPH” groups, and within the occipital cortex during the
Stroop effect condition compared to the “control MPH” group.
Results from the pre-drug analysis of baseline group effects
showed increased activation of parietal regions of MA-dependent
subjects compared to control subjects corresponding with the
Stroop effect condition. The parietal cortex plays an important role
in cognitive control, particularly response inhibition in healthy
subjects (32, 33, 39, 42, 45, 46, 96, 97). As mentioned earlier,
Stroop conflict is thought to be resolved by a stimulus-biasing
strategy (103, 109, 110) modulated by activity in the parietal
cortex (46). Hence, it was suggested that active MA-dependent
subjects require recruitment of additional neural resources within
the parietal cortex for successful conflict resolution during conflict
conditions. Results from the post-drug minus pre-drug analysis of
group–drug effects showed increased activation within the pari-
etal cortex of “control MPH” during the incongruent and Stroop
effect conditions, an effect which has been previously reported
in healthy subjects (46). Similarly to our baseline group results,
increased activation within the parietal cortex of MA-dependent
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subjects post- compared to pre-placebo administration was also
observed during the incongruent condition; however, the opposite
effect was observed in MA-dependent subjects who were treated
with MPH. In comparison to “MA placebo” subjects, “MA MPH”
subjects showed decreased activation of the left SPG during the
incongruent condition post-compared to pre-drug administra-
tion. Moreover, in comparison to “control MPH” subjects, ”MA
MPH” subjects exhibited decreased activation of the right IPL
during the incongruent condition post- compared to pre-drug
administration. These findings suggest that MPH administration
caused decreases in activation within the left superior and right
inferior parietal cortex of MA-dependent subjects during the
incongruent condition. The incongruent condition presents the
subject with a stimulus-based conflict, whereby competition exists
between two information sources: the task-relevant stimulus fea-
ture (the word color) and the task-irrelevant, but more automatic
stimulus feature (word reading) (26, 27). It is possible that with-
out treatment, active MA-dependent subjects exhibit a lowered
threshold at which incongruent stimuli present sufficient conflict
to activate the parietal cortex. In patients with ADHD, MPH treat-
ment was shown to normalize an otherwise raised threshold at
which task-related default mode network deactivation occurred,
to achieve a pattern similar to that of healthy controls (126). Simi-
larly, acute MPH treatment in active MA-dependent subjects may
normalize the threshold at which incongruent stimuli present suf-
ficient conflict to activate the parietal cortex, thereby decreasing
the activity of this region (Figure 4B).
All subjects showed increased activation within the occipi-
tal cortex post- compared to pre-drug administration during
the incongruent condition, with the exception of “MA MPH”
subjects. However, only “control MPH” subjects showed an
increase in occipital activation during the Stroop effect condi-
tion following MPH administration. These changes in activa-
tion resulted in increased activation of the occipital regions of
“MA placebo” subjects compared to “MA MPH” subjects dur-
ing the incongruent condition and of “control MPH” subjects
compared to “MA MPH” subjects during the Stroop effect con-
dition. As mentioned earlier, the visual pathways including the
occipital cortex may be involved in biasing of selective attention
toward the ink color of the presented word stimulus and away
from the task-irrelevant and prepotent response of word read-
ing (103). Our results showed that an acute dose of MPH caused
a decrease in activation of occipital regions of MA-dependent
subjects in comparison to MA-dependent subjects who were
treated with placebo. This suggests that MPH intake resulted in
a decreased need for occipital activation, while causing a simul-
taneous improvement in task performance compared to placebo.
Further, decreased activation of occipital regions of “MA MPH”
subjects compared to “control MPH” subjects suggests an MPH-
induced decrease in recruitment of occipital regions for Stroop
effect resolution that is specific to active MA-dependent sub-
jects and not healthy controls. Therefore, following an acute dose
of MPH, active MA-dependent subjects were able to undergo
successful resolution of the Stroop conflict without the need
to recruit additional resources within the occipital cortex, while
maintaining a comparable level of task performance to healthy
controls.
Although there is an established view that the ACC is activated
during conditions of information conflict, such as the incongruent
condition of the Stroop task, where two streams of informa-
tion processing compete (34, 36, 37, 40–45, 127), only “control
MPH” subjects exhibited increased activation within the ACC
and middle cingulate regions during the incongruent and Stroop
effect conditions. The increase in activation post- compared to
pre-MPH administration of cingulate regions in control subjects
may be due to increased regional cerebral blood flow to these
regions, as has been previously reported in a positron emission
tomography study of healthy subjects treated with an acute dose
of MPH (128). Although there was no significant group× drug
interaction for RT, “control MPH” subjects exhibited the largest
improvement in RT and accuracy post- compared to pre-drug
administration across incongruent and Stroop effect conditions,
relative to the three other groups. Hence, it is possible that MPH-
induced activation of the cingulate cortex may be associated with
improved behavioral performance. However, a larger dose of MPH
may be required to elicit a similar effect in active MA-dependent
subjects.
SUMMARY OF FINDINGS
At baseline, all subjects were slower and less accurate during the
incongruent compared to the congruent condition. This finding
showed that the color-word Stroop task used in the current study
probed response inhibition and consequently, cognitive control.
However, absence of fMRI activation changes in control subjects
corresponding with the Stroop effect condition indicated the task
used in the current study could benefit from increased num-
ber of blocks/task duration. MA-dependent subjects were slower
during congruent and incongruent conditions, possibly reflecting
slowed motor responses. During the incongruent condition, MA-
dependent subjects showed increased activation of the DLPFC in
comparison to control subjects, suggesting their need to recruit
frontal neural resources during response inhibition. Although
there were no significant between-group differences in Stroop
effect RT, MA-dependent subjects exhibited increased activation
of the IPL during the Stroop effect condition in comparison to
control subjects. It is possible that prior to any treatment, active
MA-dependent subjects exhibited a lowered threshold at which
incongruent stimuli present sufficient conflict to activate the pari-
etal cortex, thus exhibiting increased activation of the parietal
cortex in comparison to control subjects.
Post- minus pre-drug analysis results showed that subjects
treated with MPH had lower Stroop effect RT post- compared
to pre-drug treatment, relative to those treated with placebo. This
suggested that MPH treatment caused an improvement in task
performance in both MA-dependent and control subjects. In com-
parison to “control MPH” and “MA placebo” subjects,“MA MPH”
subjects exhibited decreases in fMRI activation of parietal and
occipital regions, which were thought to be necessary for Stroop
conflict resolution prior to drug treatment. These group differ-
ences in fMRI activation suggest that acute MPH treatment in
active MA-dependent subjects may normalize the threshold at
which incongruent stimuli present sufficient conflict to activate
the parietal cortex. Decreases in occipital cortex activation in “MA
MPH” subjects suggest that post-MPH treatment, MA-dependent
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subjects were able to maintain a comparable level of task perfor-
mance to that achieved pre-drug administration, with a decreased
need for recruitment of additional neural resources within the
occipital cortex.
LIMITATIONS
There were several limitations to the current study. The sam-
ple sizes were small (8 “MA MPH,” 7 “MA placebo,” 8 “control
MPH,” and 10 “control placebo” subjects), due to the study having
a between-subject design. These sample sizes were smaller than
those required by our a priori power analysis (129), which was
conducted using G*Power v3.1.5 (130). The significance level α
was set to 0.05, corrected for multiple comparisons; the power
level (1−β) was set to 0.8 and the effect size was estimated at
the global maximum activation co-ordinates from a single subject
effect size map of a pilot subject scan for the current experiment.
The power analysis yielded a sample size of 22 subjects per group.
However, only 15 MA-dependent subjects could be recruited, as
well as a matching 18 control subjects, who were further divided
into two treatment groups. The number of MA-dependent sub-
jects recruited for the MRI studies was limited by the completion of
the randomized controlled trial (parent trial) they were recruited
from which ended the recruitment process. Moreover, the time
difference in the commencement of the parent trial and the MRI
studies prevented retrospective recruitment of subjects from the
parent trial, due to the commencement of the MPH treatment
schedule prior to the MRI studies. Therefore, this study is con-
sidered to be underpowered, yielding insightful yet preliminary
results, which need to be consolidated by future studies with larger
sample sizes.
Another limitation to studying the effects of MA on the brain
of active users, and possibly why it is uncommon practice, is the
inability to dissociate the effects of long-term use from the poten-
tial effects of intoxication and withdrawal (28, 29). However, it
is important to investigate the functional effects of MA in active
users using neuroimaging as it is this group of drug users who most
need to be engaged in clinical trials, in the search for an effective
treatment. Furthermore, it is important to report the functional
neural correlates of cognitive processes in active MA dependence
in order to expand the literature and allow for comparisons to be
made with existing literature conducted in short- and long-term
abstinent MA-dependent individuals.
Tobacco smoking and cannabis use were more prevalent in the
MA-dependent groups. Although it was not possible to recruit
active MA-dependent subjects who did not smoke tobacco or use
cannabis, future studies should recruit a control group with similar
prevalence of tobacco and cannabis use.
Lastly, the use of fMRI to study the effects of an acute chal-
lenge of MPH in the current study was not specifically validated
in the current study; that is, the possible hemodynamic effects of
MPH on fMRI BOLD and blood perfusion were not investigated.
However, a previous fMRI study of healthy subjects using a finger
tapping task found no changes in task performance or fMRI sig-
nals following MPH administration, concluding that MPH did not
alter BOLD hemodynamic coupling (131). Consequently, fMRI
was validated as a useful tool for studying the neural correlates of
cognitive functions under the effect of MPH (131).
CONCLUSION
To the best of our knowledge, this is the first fMRI study to
investigate the effect of MPH on cognitive control in active MA-
dependent subjects in comparison to control subjects. Prior to
drug administration, accuracy was lower and RT was longer
for all subjects during the incongruent compared to congruent
condition, demonstrating the task probed cognitive control. MA-
dependent subjects were slower during congruent and incongru-
ent conditions, possibly reflecting poor motor control in compar-
ison to control subjects. During the Stroop effect condition, MA-
dependent subjects exhibited increased activation of the inferior
parietal cortex compared to control subjects, possibly reflecting a
lowered threshold at which incongruent stimuli present sufficient
conflict to activate the parietal cortex.
An acute MPH (18 mg) challenge resulted in an improvement
in task performance, manifested by a decreased Stroop interfer-
ence score in all subjects, irrespective of group membership, in
comparison to placebo. “MA MPH” subjects showed increased RT
and DLPFC activation during the Stroop effect condition post-
compared to pre-MPH treatment, suggesting an MPH-facilitated
recruitment of the DLPFC for Stroop conflict resolution. In com-
parison to “control MPH” and “MA placebo” subjects,“MA MPH”
subjects exhibited decreases in post- minus pre-drug fMRI acti-
vation of parietal and occipital regions, which were thought to
be necessary for Stroop conflict resolution prior to drug treat-
ment. Therefore, acute MPH treatment was thought to cause
normalization of the threshold at which incongruent stimuli
present sufficient conflict to activate the parietal cortex in active
MA-dependent subjects, rendering the activation pattern of “MA
MPH” subjects indistinguishable from that of untreated healthy
control subjects.
The current study provided valuable knowledge about the
effects of MPH and placebo on the neural correlates of cogni-
tive control in active MA-dependent and control subjects. Future
studies should have a larger sample size and aim to eliminate the
confounding effects of other drug use. Furthermore, larger studies
of active MA dependence using higher doses of MPH for longer
periods are recommended to consolidate the preliminary findings
from this study.
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